Clinical Trial Update: Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial assessing ipilimumab with or without bevacizumab in patients with unresectable stage IIIC/IV cutaneous melanoma; results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• ipilimumab (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 2 | Status: COMPLETED | Results posted: 2024-04-25